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license (http://creativeneurofibrillary tangles, and neurodegeneration, evidence of which may be detected in vivo via cere-
brospinal fluid (CSF) sampling. Physical activity (PA) has emerged as a possible modifier of these
AD-related pathological changes. Consequently, the aim of this study was to cross-sectionally
examine the relationship between objectively measured PA and CSF levels of Ab42 and tau in asymp-
tomatic late-middle-aged adults at risk for AD.
Methods: Eighty-five cognitively healthy late-middle-aged adults (age 5 64.31 years, 61.2% fe-
male) from the Wisconsin Registry for Alzheimer’s Prevention participated in this study. They
wore an accelerometer (ActiGraph GT3X1) for one week to record free-living PA, yielding mea-
sures of sedentariness and various intensities of PA (i.e., light, moderate, and vigorous). They
also underwent lumbar puncture to collect CSF, from which Ab42, total tau, and phosphorylated
tau were immunoassayed. Regression analyses were used to examine the association between
accelerometer measures and CSF biomarkers, adjusting for age, sex, and other relevant
covariates.
Results: Engagement in moderate PAwas associated with higher Ab42 (P 5 .008), lower total tau/
Ab42 (P 5 .006), and lower phosphorylated tau/Ab42 (P 5 .030). In contrast, neither light nor
vigorous PA was associated with any of the biomarkers. Increased sedentariness was associated
with reduced Ab42 (P 5 .014).
Discussions: In this cohort, moderate PA, but not light or vigorous, was associated with a favorable
AD biomarker profile, while sedentariness was associated with greater Ab burden. These findings
suggest that a physically active lifestyle may play a protective role against the development of AD.thor. Tel.: 608-265-4479; Fax: 608-265-3091.
ioma@medicine.wisc.edu
/j.dadm.2018.01.001
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4.0/).Keywords: Alzheimer’s disease; CSF biomarkers; Exercise; Physical activity; Sedentary behavior1. Introduction cascade, many are limited by the use of self-report ques-The preclinical stage of Alzheimer’s disease (AD) is char-
acterized by the emergence of pathognomonic brain changes
in the absence of cognitive decline [1]. These brain alterations
include amyloid b (Ab) plaques, neurodegeneration, and
neurofibrillary tangles [1]. Although these lesions are only
definitively ascertained via histologic assessments at autopsy,
it is now accepted that it is possible to probe their occurrence
ante mortem by measuring specific cerebrospinal fluid (CSF)
biomarkers intended to reflect these pathologies. These bio-
markers include Ab42, total tau (t-tau), and phosphorylated
tau (p-tau), respectively [2]. Because persons in the preclinical
stage ofAD are yet asymptomatic, they collectively represent a
unique target population for therapeutics aimed at slowing the
progression of AD pathology and ultimately preventing the
manifestation of clinical symptoms [3].
Avast body of work has shown that physical activity (PA)
ameliorates cognitive dysfunction and the risk of dementia
in the elderly [4–6], with a recent evidence review
reporting that PA is the modifiable risk factor with the
highest potential for arresting the increasing national
prevalence of AD [7]. Spurred by encouraging data from an-
imal models of AD, a growing number of human studies
have sought to determine the extent to which PA might
modulate core pathogenic markers of AD. The evolving ev-
idence suggests that higher levels of PA associate with
reduced Ab and tau burden [8–10]. Furthermore, we found
that, in a middle-aged group at increased risk for AD, those
who were physically active exhibited fewer age-related alter-
ations in Ab deposition, glucose metabolism, hippocampal
volume, and episodic memory relative to their less active
peers [11]. In addition, PA may also have the potential to
attenuate the adverse effects of genetic risk [12,13] and
poor diet [14] on Ab deposition.
Although less studied, a growing body of evidence sug-
gests that high levels of sedentary behavior (SB) may also
serve as an independent risk factor for negative outcomes
[15,16]. Studies indicate that most older adults engage in
high amounts of SB, up to 8.5 hours a day [17], and those
at risk for AD due to family history exhibit higher levels of
SB than those without a family history [18]. As such, it is
especially important to examine these behaviors among those
at risk for AD. Previous studies have examined SB among
older adults in relation to cognitive performance [19], cerebral
blood flow [20], and risk of AD [21]. However, to our know-
ledge, no study has yet examined the relationship between SB
and CSF biomarkers in older adults at risk for AD.
Furthermore, although the foregoing studies are im-
portant for providing initial evidence for potentially
disease-modifying effects of PA and SB in the ADtionnaires for ascertaining such levels. These assessment
approaches are vulnerable to measurement error stem-
ming from faulty recall, social desirability, and other
biases that might mask or inflate associations between
PA, SB, and relevant outcomes [22,23]. Recent evidence
indicates accelerometer-based measures may be more
sensitive to distinctions between PA intensities and SB
than self-report and more valuable when examining AD
outcomes [24]. Second, to our knowledge, no studies
have assessed the association between objectively
measured PA, SB, and CSF biomarkers in an asymp-
tomatic, middle-aged cohort at risk for AD. Accordingly,
the objective of this study was to investigate the relati-
onship between accelerometer-measured PA, SB, and
CSF biomarkers of AD among at-risk, late-middle-aged
adults. We specifically seek to ascertain the intensity of
PA most conducive to a favorable AD biomarker profile
and examine whether SB confers an additional risk
beyond that of low levels of PA.2. Methods
2.1. Participants
Eighty-five cognitively normal adults from the Wiscon-
sin Registry for Alzheimer’s Prevention (WRAP) partici-
pated in this study. WRAP is a longitudinal cohort
consisting of approximately 1500 late-middle-aged adults
who were cognitively healthy and between the ages of 40
and 65 years at study entry [25]. The cohort is enriched
with persons who have a parental history of AD and/or
carry 1 apolipoprotein ε4 (APOE ε4) alleles. Cognitive
normalcy was determined based on intact performance on
a comprehensive battery of neuropsychological tests,
absence of functional impairment, and absence of neuro-
logic/psychiatric conditions that might impair cognition
[11,25]. In addition, all participants were living and
functioning independently. The 85 participants for the
present study were selected based on their participation
in two WRAP substudies that included a 7-day PA assess-
ment using an accelerometer and collection of CSF via
lumbar puncture. Similar to the larger WRAP cohort, these
individuals overrepresented persons who had a parental
family history of AD (81.2%) and were APOE ε4–positive
(42.4%). Table 1 details participants’ additional back-
ground characteristics. All study procedures were approved
by the University of Wisconsin Institutional Review Board
and each participant provided informed consent before
participation.
Table 1
Participant characteristics (N 5 85)
Characteristic Value*
Age at PA assessment, years 64.31 (5.44); range: 51.58–74.23
Female, no. (%) 52 (61.2)
APOE ε4–positive, No. (%) 36 (42.4)
Family history of AD, No. (%) 69 (81.2)
Education, years 16.73 (2.82); range: 12–25
Mini-Mental State Examination 29.32 (0.98); range: 25–30
Body mass index, kg/m2 28.33 (5.32); range: 17.65–44.11
Total cholesterol, mg/dL 206.29 (38.70); range: 142–353
HDL cholesterol, mg/dL 65.00 (20.34); range: 34–121
Systolic blood pressure, mmHg 128.18 (17.46); range: 98–166
Diastolic blood pressure, mmHg 75.44 (9.09); range: 55–97
Hypertension, No. (%) 20 (23.5)
Diabetes, No. (%) 3 (3.5)
Smoker (ever), No. (%) 39 (45.9)
Sedentary % 72.35 (6.58); range: 49.00–86.36
Light PA % 18.32 (4.81); range: 7.76–30.21
Moderate PA % 7.98 (3.01); range: 2.83–18.63
Vigorous PA % 1.34 (1.18); range: .06–7.30
Met weekly PA recommendations,
no. (%)
30 (35.3)
Total accelerometer wear time per
day, hours
15.29 (1.10); range: 12.00–17.80
Abbreviations: PA, physical activity; APOE ε4, apolipoprotein E ε4
allele; AD, Alzheimer’s disease; HDL, high-density lipoprotein.
*Values indicate mean and standard deviation, unless otherwise indi-
cated.
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A triaxial accelerometer (Actigraph GT3X1; Actigraph
LLC, Pensacola, FL) measured the intensity of movement
over seven consecutive days to objectively document par-
ticipants’ free-living PA and SB during that time period. A
period of seven days is standard to ensure participants
meet standard accelerometry inclusion criteria of at least
10 hours of valid wear time per day for a minimum of 3
weekdays and 1 weekend day [26]. Participants were in-
structed to place the accelerometer on their hip, affixed to
an elastic belt, and to wear the device during all waking
hours, except while swimming or bathing. Accelerometer
data (in 1-second epochs) were processed using the
sojourn-3 axis method [27] to calculate time spent engaging
in SB and three well-established intensity categories of PA
(i.e., light, moderate, and vigorous). This method uses infor-
mation from all three axes (vertical, anterior-posterior, and
medial-lateral) to identify independent bout intervals—the
time between starting one activity (e.g., sitting, standing,
walking, running, jumping, etc.) and transitioning to
another—by instances of rapid acceleration or deceleration.
Within the sojourn-3 axis method [27], metabolic equi-
valents (METs) are determined for each bout interval using
a validated neural network approach [28], as opposed to the
traditional counts per minute approach. The MET values
that correspondwith each intensity level are as follows: seden-
tary5,1.5METs, light5 1.5–2.99METs,moderate5 3.0–
6.0METs, and vigorous5.6.0METs [26]. The totalminutes
spent participating in SB and each PA intensity category dur-ing a single daywere then divided by the total minutes ofwear
time for that day and averaged over all valid days to compute
percent of day spent in SB and each PA category.
2.3. CSF collection and analysis
Lumbar puncture for collection of CSF samples was
performed in the morning after a 12-hour fast with a Sprotte
24- or 25-gauge spinal needle at L3/4 or L4/5 using gentle
extraction into polypropylene syringes. Each sample
consisted of 22 mL of CSF, which was then combined,
gently mixed, and centrifuged at 2000 g for 10 minutes.
Supernatants were frozen in 0.5-mL aliquots in polypro-
pylene tubes and stored at280C. The samples were immu-
noassayed for Ab42, t-tau, and p-tau (at threonine 181) using
INNOTEST enzyme-linked immunosorbent assays (Fuj-
irebio, Gent, Belgium) by board-certified laboratory tech-
nicians who were blind to clinical data and used protocols
accredited by the Swedish Board for Accreditation and Con-
formity Assessment as previously described [29].
Using these data,we additionally computed t-tau/Ab42 and
p-tau/Ab42 ratios. These ratios reflect multiple aspects of AD
pathology in a singlemeasure and have been shown to possess
improved predictive and diagnostic power compared to indi-
vidual biomarkers [2,30,31]. Lower CSF Ab42 levels
indicate greater amyloid burden, while higher CSF t-tau and
p-tau levels signal greater AD pathology. Therefore,
increased t-tau/Ab42 and p-tau/Ab42 ratios indicate greater
pathology. The mean time interval between CSF sampling
and the collectionof accelerometerdatawas1.526 1.26years.
2.4. Data analysis
Tests for model assumptions [32] revealed that the PA and
SB variables were nonnormally distributed. Therefore, we
subjected them to a Blom transformation before model
fitting [33]. To address the objective of this study, that is,
an investigation into whether PA and SB are associated
with levels of CSF biomarkers for AD, we fitted a series of
covariate-adjusted linear regression models that included
terms for age, sex, APOE ε4 status, the interval between
CSF collection and accelerometer data, and assay batch.
Covariates were selected based on their known associations
with AD risk (age, sex, and APOE ε4 status) [34] or to con-
trol for interindividual variation among measures (collection
interval and assay batch). The outcome variables were the
five CSF biomarkers. A separate model was fit for each of
the three PA intensity categories and SB. All analyses
were conducted using IBM SPSS, version 24.0. Only fin-
dings with P  .05 (two-tailed) were considered significant.3. Results
3.1. Background characteristics
Participants had an average age of 64.31 6 5.44 years at
accelerometer data collection, with a majority of individuals
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APOE ε4 positive and 69 (81.2%) had a family history of
AD. Other relevant background characteristics are reported
in Table 1.
3.2. PA intensity and CSF biomarkers of AD
Light PA did not associate with any of the CSF bio-
markers, although the association between Ab42 and
light PA was in the hypothesized direction (P 5 .081).
Moderate PA was significantly associated with higher
Ab42 (P5 .008), lower t-tau/Ab42 (P5 .006), and lower
p-tau/Ab42 (P 5 .030). Vigorous PA did not associate
with any of the CSF biomarkers. These findings are re-
ported in Table 2.
To further verify the robustness of the moderate PA find-
ings, we refitted the moderate PA model while additionally
including light PA and vigorous PA as covariates. Moderate
PA remained significantly associated with lower t-tau/Ab42
(P 5 .029), but not with Ab42 (P 5 .068) or p-tau/Ab42
(P 5 .156). Interestingly, a significant association between
greater moderate PA and lower t-tau also emerged (b stan-
dard error [SE] 5 238.57 [19.07], P 5 .047). However,
these results should be interpreted with caution as the issue
of multicollinearity may be a factor. Moderate PAwas signif-
icantly correlated with both light PA (r 5 0.239, P 5 .027)
and vigorous PA (r5 0.555, P, .001). In addition, the mod-
erate and vigorous PAvariables suffered from low tolerance,
another indicator of multicollinearity [32] (12 R25 0.717;
tolerance values were as follows: light PA 5 0.815, mo-
derate PA 5 0.611, vigorous PA 5 .649).
3.3. SB and CSF biomarkers of AD
Greater SB was significantly associated with lower Ab42
(P 5 .014) (Table 2), but not with any of the other bio-
markers. To examine SB as an independent risk factor, we
refitted the model to also include moderate PA as a covariate.
Upon inclusion, SB was no longer associated with any CSF
biomarkers. However, multicollinearity may again be an
issue as SB and moderate PA are highly correlated
(r 5 20.677, P , .001) and both variables exhibited lowTable 2
Association between intensity of physical activity and CSF biomarkers
Biomarker
Sedentary Light
b (SE) P b (SE) P
Ab42 254.12 (21.52) .014 39.47 (22.35) .0
t-tau 22.89 (15.28) .850 9.88 (15.53) .5
p-tau 21.45 (1.56) .356 1.57 (1.59) .3
t-tau/Ab42 20.05 (0.03) .109 20.03 (0.03) .3
p-tau/Ab42 0.01 (0.01) .161 20.01 (0.01) .4
NOTE.Models were adjusted for age, sex,APOE ε4 status, interval between CSF
(b) refers to the amount of change in each biomarker for every 1% change in time s
Italicized values refer to associations where .05 , P , .10.
Abbreviations: CSF, cerebrospinal fluid; b, regression estimate; SE, standard err
apolipoprotein E ε4 allele.tolerance (12R25 0.711; tolerance values were as follows:
SB 5 0.459, moderate PA 5 0.425).
To display these moderate PA (Fig. 1) and SB (Fig. 2)
findings, the participants were divided into three groups, im-
plemented separately for moderate PA and SB: lowest 25th
percentile (n 5 21), middle 50th percentile (n 5 43), and
highest 25th percentile (n 5 21). Mean 6 SE levels of
CSF biomarkers were plotted for each group.
3.4. Supplemental analyses
Because the literature often looks atmoderate and vigorous
PA in combination as a measure of health-enhancing behavior
[35–38], we reanalyzed the data after pooling together
moderate and vigorous PA into a composite measure of
moderate-to-vigorous PA (MVPA) as the PA intensity of inter-
est. The results remained essentially the same, with MVPA
associated with higher Ab42 (b [SE] 5 62.16 [22.43],
P 5 .007), lower t-tau/Ab42 (b [SE] 5 20.09 [0.03],
P 5 .007), and lower p-tau/Ab42 (b [SE] 5 20.01 [0.01],
P 5 .020). Given these results and the moderate PA findings
reported previously, it would appear moderate PA is the
more potent of the two PA intensities and is driving the asso-
ciations between MVPA and these CSF biomarkers.4. Discussion
To our knowledge, this is the first study to investigate the
association between objectively measured PA, SB, and CSF
biomarkers in a cognitively unimpaired, middle-aged cohort
at risk for AD. Our findings show that increased moderate
PA is associated with a favorable biomarker profile (i.e.,
higher levels of CSF Ab42 and lower t-tau/Ab42 and p-
tau/Ab42 ratios), while SB is associated with greater AD
pathophysiology (i.e., lower levels of CSF Ab42). We did
not observe any significant associations between light or
vigorous PA and CSF biomarkers, indicating a moderate
level of PA may be the most beneficial intensity of PA for
forestalling alterations in AD pathophysiology.
These findings are broadly consistent with previous
studies. Specifically, past reports have found PA to be bene-
ficial in promoting a favorable AD biomarker profile,Moderate Vigorous
b (SE) P b (SE) P
81 60.74 (22.27) .008 35.42 (23.45) .135
26 224.31 (15.68) .125 21.79 (16.25) .913
27 20.46 (1.63) .779 20.11 (1.67) .947
66 20.09 (0.03) .006 20.05 (0.04) .150
02 20.01 (0.01) .030 20.01 (0.01) .101
collection and accelerometer data, and assay batch. The regression estimate
pent in each PA category. Bolded values refer to associations where P, .05.
or; Ab42, amyloid b 42; t-tau, total tau; p-tau, phosphorylated tau; APOE ε4,
Fig. 1. Association between moderate PA and CSF biomarkers. Participants were divided into lowest 25th (n 5 21), middle 50th (n 5 43), and highest 25th
(n5 21) percentiles according to moderate PA levels; and mean Ab42 (A), t-tau (B), p-tau (C), t-tau/Ab42 (D), and p-tau/Ab42 (E) levels of each group were
plotted. Figures reflect values adjusted for age, sex, APOE ε4 status, the interval between CSF collection and accelerometer data, and assay batch. Abbrevia-
tions: PA, physical activity; CSF, cerebrospinal fluid; Ab42, amyloid b 42; t-tau, total tau; p-tau, phosphorylated tau; a.u., arbitrary units; APOE ε4, apolipo-
protein E ε4 allele.
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age-related changes in Ab deposition, glucose metabolism,
hippocampal volume, and episodic memory [11]. Further-
more, our findings of the benefits of moderate-intensity PA
in particular are supported by previous research. Geda et al.
[39] found moderate-intensity PA in both midlife and late
life to be associated with a reduced risk of developing cogni-
tive impairment later in life, while light- and vigorous-
intensity PA did not confer the same benefits. In addition to
cognitive advantages, moderate PA has been favorably corre-
lated with other AD-related markers. A recent study by our
group [40] found moderate PA to be associated with
increased cerebral glucose metabolism in 6 brain regions of
interest, while vigorous-intensity PA was only associated
with one region and light-intensity with none. In addition,
in a study by Doi et al. [41], objectively measured MVPA
was associated with less brain atrophy among older adults
with mild cognitive impairment, while light PA was not. A
study by the same group also found moderate, but not light
PA, to be associated with increased hippocampal volume in
the same mild cognitive impairment cohort [42]. These
studies complement our moderate PA finding, suggesting
that moderate-intensity activity may be the most advanta-
geous level of PA for older adults to see benefits.
Although our study did not directly examine potential
mechanisms, moderate PA may protect against adversebiomarker changes by increasing cerebral blood flow; reducing
insulin resistance; reducing the risk of cardiovascular disease
(CVD) and cerebrovascular disease; or increasing production
of growth factors, such as brain-derived neurotrophic factor
[39,43]. It is possible that light PA on its own is not
sufficient to produce these benefits. This is consistent with
the PA recommendations set by the American College of
Sports Medicine and the American Heart Association,
which suggest a minimum of 150 minutes of moderate PA
or 60 minutes of vigorous PA per week, in addition to the
light-intensity activities of daily living [44]. It should also
be noted that our lack of findings for vigorous PA should be
interpreted with caution; our analyses are limited by our
sample’s restricted range on time spent engaging in vigorous
PA (Table 1). Older adults are overall less likely to engage in
vigorous PA [26], and this limitation has been observed by
others as well [45].
Furthermore, our findings show that increased SB is asso-
ciatedwith a less favorable AD biomarker profile, specifically
lower levels of CSF Ab42. SB refers to any activity that is
done seated or in a reclined posture, including watching tele-
vision, using a computer, or sitting in a car [16]. Emerging
studies suggest that SB may serve as an independent risk fac-
tor for adverse outcomes [15]. Many individuals meet recom-
mended PA guidelines, while also engaging in significant
amounts of SB, which may have a deleterious effect on
Fig. 2. Association between sedentariness and CSF biomarkers. Participants were divided into lowest 25th (n 5 21), middle 50th (n 5 43), and highest 25th
(n5 21) percentiles according to sedentariness levels; and mean Ab42 (A), t-tau (B), p-tau (C), t-tau/Ab42 (D), and p-tau/Ab42 (E) levels of each group were
plotted. Figures reflect values adjusted for age, sex, APOE ε4 status, the interval between CSF collection and accelerometer data, and assay batch. Abbrevia-
tions: CSF, cerebrospinal fluid; Ab42, amyloid b 42; t-tau, total tau; p-tau, phosphorylated tau; a.u., arbitrary units; APOE ε4, apolipoprotein E ε4 allele.
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fect of PA [16]. Previous studies have found increased seden-
tary time to be associated with a higher risk of all-cause
mortality [46–48] and death due to CVD [47,49], even after
accounting for PA. Not only does SB contribute to risk of
death, it is also associated with a greater risk of CVD [50]
and CVD risk factors [51], including high triacylglycerol
level, low high-density lipoprotein (HDL)-cholesterol, and
high fasting blood glucose. Among older adults, one study
found SB to be independently associated with worsened
cognitive function [52]. To date, no studies have examined
SB and CSF biomarkers. Our results support previous litera-
ture indicating the negative effects of SB, while also offering
new information about its adverse relationship with AD path-
ophysiology specifically.
Even so, this study is not without limitations. Its cross-
sectional design restricts our ability to establish a causal
relationship between PA and biomarker levels. Future
studies within the context of a prospective design would
be valuable in further elucidating the association between
PA, SB, and CSF biomarkers of AD. Another limitation is
the lack of contemporaneous lifestyle data, such as dietary
habits and sleep hygiene, which may benefit future studies
in identifying other lifestyle factors that may influence
biomarker levels or play a role in these disease processes.
In addition, the time interval between PA assessment and
CSF collection (1.52 6 1.26 years) poses another limitationto our study. By controlling for this time interval, we hoped
to limit its effect on our results. Future studies might benefit
from collecting all data more contemporaneously. Finally,
the generalizability of our results to the larger population
is limited. First, the level of PA in our sample is much higher
than the general population of late-middle-aged adults:
35.3% of our sample met the weekly PA recommendations
[53], while the reported national average is less than 5%
[26]. In addition, our sample is relatively homogenous
with regard to race and education, as most participants
were non-Hispanic whites and well educated.
In conclusion, this study presents novel findings
regarding the relationship between objectively measured
PA and CSF biomarkers of AD. Our results suggest that
limiting SB and engaging in moderate PA may produce
beneficial effects on CSF biomarkers of AD, particularly
among late-middle-aged adults at risk for the disease. How-
ever, given the novelty of our study, future investigations
examining objectively measured PA and biomarkers of AD
pathophysiology are needed to further validate our findings.
In particular, additional exploration of the effects of moder-
ate PA, versus light and vigorous, and the unique risk
conferred by SB would be extremely valuable. Overall,
this study reinforces previous literature on the benefits of
PA for overall health and suggests PA may be an important
tool in staving off adverse midlife pathophysiological
changes related to AD.
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1. Systematic review: We searched PubMed using the
following search terms: “physical activity,” “actigra-
phy,” “accelerometry,” “cerebrospinal fluid,” “CSF bio-
markers,” “sedentary behavior,” “sedentariness,” and
“Alzheimer’s disease.”We also reviewed the references
for each article identified.
2. Interpretation: Midlife interventions to slow or pre-
vent pathological changes related to Alzheimer’s
disease are of great scientific interest. Our findings
show that, among cognitively healthy, late-middle-
aged adults, levels of moderate physical activity
and sedentariness are associated with cerebrospinal
fluid levels of amyloid and tau. These results are
consistent with previous studies suggesting a
physically active lifestyle may play a protective
role against the development of Alzheimer’s dis-
ease.
3. Future directions: Future studies should further in-
vestigate the unique influence of moderate-intensity
physical activity, versus light or vigorous, and
sedentary behavior on cerebrospinal fluid bio-
markers. Studies in the context of a prospective
design would be of particular value.References
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